With COVID, flu and RSV creating what many are calling a tripledemic, new research is shedding light on the effect the different COVID-19 variants have had on the youngest of patients throughout the pandemic and the role ...
Jan 12, 2023
0
7
China on Saturday said it had given "conditional" approval for Pfizer's COVID-19 drug Paxlovid to treat adults with mild to moderate illness and a high risk of developing severe disease.
Feb 12, 2022
0
8
The SARS-CoV-2 omicron variant's "milder" outcomes are likely due to more population immunity rather than the virus' properties, according to a paper by William Hanage, associate professor of epidemiology at Harvard T.H. ...
Feb 3, 2022
7
268
An Omicron case has been detected in Beijing, officials in the Chinese capital said Saturday, as the country battles multiple outbreaks of the highly transmissible coronavirus variant ahead of the Winter Olympics.
Jan 16, 2022
0
16
An early look at the performance of COVID-19 booster shots during the recent omicron wave in the U.S. hinted at a decline in effectiveness, though the shots still offered strong protection against severe illness.
Feb 11, 2022
0
75
A study released in JAMA Network Open by investigators at Providence, one of the largest health systems in the United States, and the University of Chicago, found that the level of protection granted by a prior symptomatic ...
Apr 20, 2022
0
22
A small increase in the number of people having two vaccines against COVID-19 was more effective in controlling the virus during Europe's fourth wave—when the omicron variant appeared—than the rapid uptake of booster ...
Nov 16, 2022
0
47
Many treatments for COVID-19 focus on the spike protein that the virus uses to bind to human cells. While those treatments work well on the original variant, they may not be as effective on future ones. The Omicron variant, ...
Jan 12, 2022
0
225
Researchers say they've uncovered a clue to why the Omicron variant spreads COVID-19 so much more rapidly than its predecessors.
Jan 10, 2022
0
101
High levels of mucosal IgA antibodies in the airways protect against SARS-CoV-2 infection for at least eight months. Omicron infection generates durable mucosal antibodies, reducing the risk of re-infection. These are the ...
Jan 16, 2023
0
37
